Possíveis ligações entre a osteoporose e a doença periodontal

Penoni, Daniela Cia; Leão, Anna Thereza Thomé; Fernandes, Tatiana; Torres, Sandra Regina

doi:10.1016/j.rbr.2015.12.002

Cited by 12 publications

(6 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A number of studies showed that there is a relationship between oral and systemic bone loss as well as an association of osteoporosis with periodontal diseases (14)(15)(16) . Estrogen hormone plays vital protective effect as antiresorptive agent on alveolar bone, since it improve OPG production and decrease RANKL expression, therefore estrogen deficiency after menopause considered as a key feature for development of osteoporosis (17) , progression of periodontitis, alveolar bone resorption, and osteoporotic changes in the jaw (18) . Bone resorption and formation is regulated by the quantity of RANKL and RANK on the osteoclast surface and the presence of OPG (5) that inhibit osteoclast function and prevent bone resorption through binding to RANKL (19) .…”

Section: Discussionmentioning

confidence: 99%

Effect of Alendronate Treatment on Salivary Levels of Osteoprotegrin and TNF-α in Postmenopausal Woman with Osteoporosis and Periodontal Diseases

Ibraheem¹,

Mohammed²

2018

JBCD

View full text Add to dashboard Cite

Background: All diseases concerning bone destruction such as osteoporosis and periodontal diseases share common pattern in which the osteoclast cells are absolutely responsible for bone resorption that occurred when osteoclast activity exceeds osteoblast activity. Osteoprotegrin (OPG) considered as novel soluble decoy receptor known as “bone protector” since it prevents extreme bone resorption through inhibition of differentiation and activity of osteoclast by competing for binding site. It binds to receptor activator of nuclear factor kappa-B ligand (RANKL) and prevent its interaction with receptor activator of nuclear factor kappa-B (RANK), thus inhibits osteoclast formation. TNF-α is a pro-inflammatory cytokines having a broad range of important roles in regulation of immune system and bone resorption through the stimulation of osteoclastogenesis. Alendronate (ALN) diminishes the expression of osteoclast activating factors and cytokines such as RANKL and enhances the production of decoy receptor osteoprotegerin in osteoblast cells. Moreover, it decreases the production of proinflammatory cytokines such as TNF-α by macrophage, stimulates apoptosis of monocyte-macrophage cell lines derivative and reduces inflammatory response. Aims of the Study: 1. To assess the effect of alendronate treatment on salivary levels of osteoprotegrin and TNF-α in postmenopausal women with osteoporosis and periodontal disease 2. To find any possible correlation between salivary levels of osteoprotegrin and TNF-α in control and study groups. Materials and Methods: Total sample of 90 female subjects (55-65 years) were divided into 3 groups, (30 subjects in each group): first control group involved systemically healthy subjects with healthy periodontium, second group involved postmenopausal women with osteoporosis under alendronate treatment for(3-6)months (alendronate group), third group involved postmenopausal women with osteoporosis without alendronate treatment(osteoporosis group). The last two groups were sub- divided in- to two sub –groups (15 subjects in each sub-group) of gingivitis and periodontitis subjects respectively. Salivary samples were collected from all subjects and salivary levels of osteoprotegrin and TNF- α were determined by enzyme –linked immune sorbent assay (ELISA). Results: Highest median value of salivary (OPG) was found in alendronate group followed by control group while the lowest value was found in osteoporosis group. Highest median value of TNF- α was found in osteoporosis group followed by control group and alendronate group respectively with highly significant differences between them. Spearman correlation between salivary levels of TNF-α and OPG showed non- significant correlation at all subgroups. Conclusion: Subjects with osteoporosis in this study had greater levels of TNF-α and decrease in the level of OPG comparing with patients under alendronate treatment. Alendronate treatment for women with osteoporosis and periodontal disease may have beneficial outcome.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of Alendronate Treatment on Salivary Levels of Osteoprotegrin and TNF-α in Postmenopausal Woman with Osteoporosis and Periodontal Diseases

Ibraheem¹,

Mohammed²

2018

JBCD

View full text Add to dashboard Cite

show abstract

“…NF-κB activation increases production of pro-inflammatory cytokine and its precursors and may affect the risk of developing infection, chronic inflammation, cancer and age-related diseases such as osteoporosis [29]. Recent studies suggest that there is a relationship between osteoporosis and periodontal disease, both diseases are characterized by bone loss [30][31][32]. Studies investigating the relationship between periodontal diseases and NOD1/NOD2 have shown that these proteins play a role in induction of innate immune responses and bone resorption [33][34][35].…”

Section: Introductionmentioning

confidence: 99%

Genetic variation in NOD1/CARD4 and NOD2/CARD15 immune sensors and risk of osteoporosis

et al. 2020

View full text Add to dashboard Cite

Abstract The present study was aimed to investigate the relationship between NOD1/CARD4 and NOD2/CARD15 gene polymorphisms and osteoporosis in the Turkish population. The first time we thought that the functional polymorphisms in NOD1/CARD4 and NOD2/CARD15 genes might have triggered the development of osteoporosis. The objective of our study was to determine the relationship between NOD1/CARD4 and NOD2/CARD15 SNPs and osteoporosis. The NOD1/CARD4 (rs5743336) and NOD2/CARD15 (rs2066847) SNPs were analyzed by PCR restriction fragment length polymorphism (PCR-RFLP) in 94 healthy controls and 164 subjects with osteoporosis. PCR products were digested with restriction enzymes AvaI for NOD1/CARD4 and ApaI for NOD2/CARD15. We found that NOD1/CARD4 genotype distribution of AA, GA and GG were 15, 44 and 41% for patients and 17, 46 and 37% for controls, respectively. NOD2/CARD15 mutation was found only in three patients (1.8%) as heterozygote. The results did not show any statistical difference between NOD1/CARD4 and NOD2/CARD15 genotype distribution of patients and healthy groups (χ2 = 1.740, P=0.187; χ2 = 1.311, P=0.519). However, the most frequent AG genotype (46%) of NOD1/CARD4 was observed in healthy controls, GG genotype (44%) of NOD1/CARD4 was observed as the most frequent in osteoporotic patients. NOD2/CARD15 WT/WT genotype, the most frequent genotype, was observed in both groups. Statistical analysis revealed that NOD1/CARD4 and NOD2/CARD15 polymorphisms are not associated with osteoporosis. However, a definite judgement is difficult to be made due to restricted number of patients and small size of control group. Further research is sorely warranted in this direction.

show abstract

“…O tecido ósseo sofre um constante processo de homeostase/remodelação, dentro do qual os osteoblastos e os osteoclastos são os principais protagonistas; e esse processo é regulado ainda por uma série de elementos e fatores sinalizadores. Portanto, qualquer alteração neste equilíbrio, pode provocar uma modificação na densidade mineral óssea, situação observada em certas doenças inflamatórias como osteoporose, artrite reumatóide e periodontite (Adamopoulos & Mellins, 2015;Penoni et al, 2016).…”

Section: Tecido óSseounclassified

Papel da frutose 1,6-bisfosfato na osteoclastogênese e reabsorção óssea <i>in vitro</i>

Buitrago¹

View full text Add to dashboard Cite

show abstract

Possíveis ligações entre a osteoporose e a doença periodontal

Cited by 12 publications

References 24 publications

Effect of Alendronate Treatment on Salivary Levels of Osteoprotegrin and TNF-α in Postmenopausal Woman with Osteoporosis and Periodontal Diseases

Effect of Alendronate Treatment on Salivary Levels of Osteoprotegrin and TNF-α in Postmenopausal Woman with Osteoporosis and Periodontal Diseases

Genetic variation in NOD1/CARD4 and NOD2/CARD15 immune sensors and risk of osteoporosis

Papel da frutose 1,6-bisfosfato na osteoclastogênese e reabsorção óssea <i>in vitro</i>

Contact Info

Product

Resources

About